"Anthracyclines" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Organic compounds that have a tetrahydronaphthacenedione ring structure attached by a glycosidic linkage to the amino sugar daunosamine.
| Descriptor ID |
D018943
|
| MeSH Number(s) |
D02.455.426.559.847.562.050 D04.615.562.050 D09.408.051.059
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Anthracyclines".
Below are MeSH descriptors whose meaning is more specific than "Anthracyclines".
This graph shows the total number of publications written about "Anthracyclines" by people in this website by year, and whether "Anthracyclines" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2005 | 0 | 2 | 2 |
| 2007 | 1 | 1 | 2 |
| 2010 | 1 | 1 | 2 |
| 2011 | 1 | 0 | 1 |
| 2012 | 2 | 1 | 3 |
| 2013 | 3 | 0 | 3 |
| 2014 | 3 | 0 | 3 |
| 2015 | 1 | 0 | 1 |
| 2016 | 2 | 0 | 2 |
| 2017 | 1 | 2 | 3 |
| 2018 | 1 | 0 | 1 |
| 2020 | 2 | 0 | 2 |
| 2021 | 0 | 1 | 1 |
| 2022 | 0 | 1 | 1 |
| 2024 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Anthracyclines" by people in Profiles.
-
Intensification of upfront chemotherapy for patients with myeloid blast phase CML: a single center experience. Ann Hematol. 2024 Dec; 103(12):5395-5403.
-
Low-grade fibromyxoid sarcoma and sclerosing epithelioid fibrosarcoma, outcome of advanced disease: retrospective study from the Ultra-Rare Sarcoma Working Group. ESMO Open. 2024 Sep; 9(9):103689.
-
Risk of anthracycline-induced cardiac dysfunction in adolescent and young adult (AYA) cancer survivors: role of genetic susceptibility loci. Pharmacogenomics J. 2024 Jun 29; 24(4):21.
-
Obesity Predisposes Anthracycline-Treated Survivors of Childhood and Adolescent Cancers to Subclinical Cardiac Dysfunction. Pediatr Cardiol. 2025 Feb; 46(2):362-371.
-
Guidelines for Standardization of Pediatric Anthracycline Cardiomyopathy Echocardiogram Surveillance-A Call for Harmonization in the Field to Enhance Research in the Cancer Survivor Population. Pediatr Cardiol. 2024 02; 45(2):452-453.
-
Adolescent and young adult Hodgkin lymphoma patients at risk for subcutaneous fat gain during early cancer treatment: a brief report. Leuk Lymphoma. 2024 Jan; 65(1):62-68.
-
Early skeletal muscle loss in adolescent and young adult cancer patients treated with anthracycline chemotherapy. Cancer Med. 2023 11; 12(22):20798-20809.
-
Neoadjuvant Talazoparib in Patients With Germline BRCA1/2 Mutation-Positive, Early-Stage Triple-Negative Breast Cancer: Results of a Phase II Study. Oncologist. 2023 10 03; 28(10):845-855.
-
Subsequent female breast cancer risk associated with anthracycline chemotherapy for childhood cancer. Nat Med. 2023 09; 29(9):2268-2277.
-
Inhibition of Galectin-9 sensitizes tumors to anthracycline treatment via inducing antitumor immunity. Int J Biol Sci. 2023; 19(14):4644-4656.